Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4000
Buy Report View Sample

Published: November 30, 2020 Report Code: GDME1042EPD-ST

Select Item

Liver Cancer Diagnostic Tests include assays of mostly antibodies released in response to a liver cancer and cancer-causing proteins. GlobalData's Medical Devices sector report, “Liver Cancer Diagnostic Tests-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Liver Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
The Liver Cancer Diagnostic Tests Pipeline Assessment report provides key information and data related to:
Extensive coverage of the Liver Cancer Diagnostic Tests under development
Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates
Reviews of major players involved in the pipeline product development.
Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Liver Cancer Diagnostic Tests pipeline products.
Review of Recent Developments in the segment / industry
The Liver Cancer Diagnostic Tests Pipeline Assessment report enables you to:
Access significant competitor information, analysis, and insights to improve your R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development
Formulate market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
The major companies covered in the “Liver Cancer Diagnostic Tests- Medical Devices Pipeline Assessment, 2020” report:
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
The GlobalData Differentiation

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

The data and analysis within this report are driven by GlobalData Medical Intelligence Center (GDMIC) database. GDMIC gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following:

• 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2015 and forecast to 2025
• 6,700+ industry-leading analysis reports covering sector reports, medipoint reports, country analysis, expert insights and industry analysis (devices and procedures) reports
• 64,000+ medical equipment company profiles
• 5,600+ company profiles of medical equipment manufacturers in China and India
• 2,200+ company profiles of medical equipment manufacturers in Japan
• 1,200+ companies’ revenue splits and market shares
• 1,600+ quarterly and annual medical equipment company financials
• 850+ medical equipment company SWOTs
• 28,000+ pipeline product profiles
• 56,400+ marketed product profiles
• 47,000+ clinical trials
• 41,500+ trial investigators
• 7,000+ reports on companies with products in development
• 44,000+ deals in the medical equipment industry
• 1,100+ surgical and diagnostic procedures by therapy area
• 50+ key healthcare indicators by country
• 431,000+ Themes Content Items
• 600+ Influencers
• 1,900+ Analysts & Researchers
• 0.5m+ Community Members
• 141,000+ Macroeconomic Indicators
• 1,013,000+ City Indicators

For more information or to receive a free demonstration of the service, please visit:
https://medical.globaldata.com/home.aspx
Custom Requirements
Contact us to discuss the areas of your business where you need external input, and we will work with you to identify the strongest way forward to meet your needs.

Scope

– Extensive coverage of the Liver Cancer Diagnostic Tests under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Liver Cancer Diagnostic Tests and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of Liver Cancer Diagnostic Tests under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the product’s current stage of development, territory and estimated launch date

Abbott Diagnostics
Abcodia Ltd
AXO Science SAS
BioMark Technologies Inc
Bioprognos SL
China Sky One Medical Inc
Digna Biotech SL
Exact Sciences Corp
German Cancer Research Center
Glycotest Inc
Glympse Bio Inc
ImCare Biotech LLC
Imperial College London
IntegraGen SA
IPDx Immunoprofiling Diagnostics GmbH
JBS Science Inc
Matrix-Bio Inc
MDNA Life Sciences Inc
Medical University of South Carolina
Medical University of Vienna
Memorial Sloan Kettering Cancer Center
NanoString Technologies Inc
Northwestern University
Numares AG
Oncimmune (USA) LLC
Orion Genomics LLC
PleX Diagnostics Inc (Inactive)
ProMIS Neurosciences Inc
Proplex Technologies Llc
Proteome Sciences Plc
Roche Diagnostics International Ltd
University of Hong Kong
University of Louisville
University of Rochester
Ventana Medical Systems Inc
Viomics Inc.
XEPTAGEN SpA
Ymir Genomics LLC.

Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Liver Cancer Overview 8

3 Products under Development 9

3.1 Liver Cancer – Pipeline Products by Stage of Development 9

3.2 Liver Cancer – Pipeline Products by Territory 10

3.3 Liver Cancer – Pipeline Products by Regulatory Path 11

3.4 Liver Cancer – Pipeline Products by Estimated Approval Date 12

3.5 Liver Cancer – Ongoing Clinical Trials 13

4 Liver Cancer – Pipeline Products under Development by Companies 14

4.1 Liver Cancer Companies – Pipeline Products by Stage of Development 14

4.2 Liver Cancer – Pipeline Products by Stage of Development 16

5 Liver Cancer Companies and Product Overview 18

5.1 Abbott Diagnostics Company Overview 18

5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18

5.2 Abcodia Ltd Company Overview 23

5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 23

5.3 AXO Science SAS Company Overview 24

5.3.1 AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview 24

5.4 BioMark Technologies Inc Company Overview 27

5.4.1 BioMark Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.5 Bioprognos SL Company Overview 28

5.5.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 28

5.6 China Sky One Medical Inc Company Overview 29

5.6.1 China Sky One Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 29

5.7 Digna Biotech SL Company Overview 30

5.7.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 30

5.8 Exact Sciences Corp Company Overview 32

5.8.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 32

5.9 German Cancer Research Center Company Overview 34

5.9.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 34

5.10 Glycotest Inc Company Overview 35

5.10.1 Glycotest Inc Pipeline Products & Ongoing Clinical Trials Overview 35

5.11 Glympse Bio Inc Company Overview 38

5.11.1 Glympse Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.12 ImCare Biotech LLC Company Overview 39

5.12.1 ImCare Biotech LLC Pipeline Products & Ongoing Clinical Trials Overview 39

5.13 Imperial College London Company Overview 40

5.13.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 40

5.14 IntegraGen SA Company Overview 41

5.14.1 IntegraGen SA Pipeline Products & Ongoing Clinical Trials Overview 41

5.15 IPDx Immunoprofiling Diagnostics GmbH Company Overview 42

5.15.1 IPDx Immunoprofiling Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 42

5.16 JBS Science Inc Company Overview 43

5.16.1 JBS Science Inc Pipeline Products & Ongoing Clinical Trials Overview 43

5.17 Matrix-Bio Inc Company Overview 44

5.17.1 Matrix-Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 44

5.18 MDNA Life Sciences Inc Company Overview 46

5.18.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 46

5.19 Medical University of South Carolina Company Overview 47

5.19.1 Medical University of South Carolina Pipeline Products & Ongoing Clinical Trials Overview 47

5.20 Medical University of Vienna Company Overview 48

5.20.1 Medical University of Vienna Pipeline Products & Ongoing Clinical Trials Overview 48

5.21 Memorial Sloan Kettering Cancer Center Company Overview 49

5.21.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 49

5.22 NanoString Technologies Inc Company Overview 50

5.22.1 NanoString Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 50

5.23 Northwestern University Company Overview 51

5.23.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 51

5.24 Numares AG Company Overview 52

5.24.1 Numares AG Pipeline Products & Ongoing Clinical Trials Overview 52

5.25 Oncimmune (USA) LLC Company Overview 53

5.25.1 Oncimmune (USA) LLC Pipeline Products & Ongoing Clinical Trials Overview 53

5.26 Orion Genomics LLC Company Overview 54

5.26.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 54

5.27 PleX Diagnostics Inc (Inactive) Company Overview 55

5.27.1 PleX Diagnostics Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 55

5.28 ProMIS Neurosciences Inc Company Overview 56

5.28.1 ProMIS Neurosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 56

5.29 Proplex Technologies Llc Company Overview 57

5.29.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 57

5.30 Proteome Sciences Plc Company Overview 58

5.30.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 58

5.31 Roche Diagnostics International Ltd Company Overview 59

5.31.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 59

5.32 University of Hong Kong Company Overview 60

5.32.1 University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 60

5.33 University of Louisville Company Overview 62

5.33.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 62

5.34 University of Rochester Company Overview 63

5.34.1 University of Rochester Pipeline Products & Ongoing Clinical Trials Overview 63

5.35 Ventana Medical Systems Inc Company Overview 64

5.35.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.36 Viomics Inc. Company Overview 65

5.36.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 65

5.37 XEPTAGEN SpA Company Overview 66

5.37.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 66

5.38 Ymir Genomics LLC. Company Overview 70

5.38.1 Ymir Genomics LLC. Pipeline Products & Ongoing Clinical Trials Overview 70

6 Liver Cancer- Recent Developments 71

6.1 Sep 30, 2020: Skoltech scientists discovered a new biomarker for liver cancer diagnosis 71

6.2 Jul 30, 2020: Blueprint Medicines reports second quarter 2020 financial results 71

6.3 Jun 24, 2020: Novel radiotracer proves advantageous for imaging neuroendocrine tumor patients with liver-dominant disease 74

6.4 Jun 15, 2020: Study demonstrates feasibility of hologram technology in liver tumor ablation 74

6.5 Jun 02, 2020: Pfizer establishes new program to support continued biotechnology innovation 75

6.6 May 12, 2020: National Cancer Institute renews Jackson Laboratory’s Cancer Center Designation 76

6.7 Feb 27, 2020: James Quincey elected to Pfizer’s board of directors 77

6.8 Feb 14, 2020: Pfizer: Appointment of Mr. Samir Kazi as an executive director 77

6.9 Feb 14, 2020: Pfizer: Resignation of Mr. Vivek Dhariwal 78

6.10 Feb 13, 2020: Blueprint Medicines reports fourth quarter and full year 2019 financial results 78

6.11 Jan 28, 2020: Pfizer reports fourth-quarter and full-year 2019 results 80

6.12 Jan 27, 2020: PerkinElmer announces financial results for the fourth quarter 87

6.13 Jan 13, 2020: Blueprint Medicines announces 2020 corporate goals 89

6.14 Jan 02, 2020: Pfizer, Sanofi and GlaxoSmithKline plan to increase US drug prices in 2020 90

6.15 Dec 18, 2019: Pfizer and Mylan announce two future Viatris board members 90

6.16 Dec 16, 2019: Pfizer declares first-quarter 2020 dividend and announces upcoming investor day to highlight strength of innovative R&D pipeline 91

7 Appendix 92

7.1 Methodology 92

7.2 About GlobalData 96

7.3 Contact Us 96

Frequently asked questions

Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

Most Popular
$8,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
United States Surgical Energy Instruments Market Size (Value, Volume, ASP)…
$500 | November 2020
Medical Devices
Argentina Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Medical Devices
Brazil Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 in real time.

  • Access a live Liver Cancer Diagnostic Tests – Medical Devices Pipeline Assessment, 2020 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more